Executive Summary
Ukraine’s AI-biotechnology sector is developing under the extraordinary pressures and opportunities of full-scale war. Unlike Russia’s state-directed, sovereignty-focused model, Ukraine’s approach is characterized by agile public-private partnerships, reliance on Western technology transfer, and a dual imperative: addressing immediate wartime medical needs (antibiotic-resistant infections, rehabilitation) while laying foundations for post-war economic recovery. Verified developments include: a first-in-Eastern-Europe AI-powered phage therapy project for treating antibiotic-resistant infections in wounded soldiers, launched with British partner GutSee Health ; a Dutch-Ukrainian startup (Gamow Tech) applying computer vision to IVF oocyte assessment, backed by Ukrainian venture capital ; a €75 million blood plasma processing facility under construction in Zakarpattia with 1.5 million liter annual capacity ; and foundational AI research on cellular protein interaction modeling at the National Academy of Sciences . However, the sector faces persistent challenges: fragmented institutional coordination, limited domestic AI infrastructure, and an innovation ecosystem still heavily dependent on international partnerships and wartime urgency rather than systematic state investment.
- The Strategic Framework: Wartime Adaptation and Digital Strategy
Ukraine’s AI-biotech development is embedded within two overarching strategic documents. The WINWIN Strategy for Digital Development and Innovation until 2030 serves as the primary coordination mechanism, explicitly aiming to integrate AI into key sectors “from healthcare to defence” and position Ukraine as a “global centre for technological solutions” . Separately, the Concept of Bioeconomy Development until 2030 and the Biosafety Strategy provide sector-specific frameworks for biotechnology innovation, covering pharmaceuticals, agrobiotechnology, and bioenergy .
A 2026 academic analysis published in Development Management established that Ukraine’s state policy creates “systemic conditions” for biotech innovation, and identified the interaction between Ukraine’s IT sector and biotechnology as a competitive advantage that “accelerates the transformation of scientific potential into commercial products” . This IT-biotech synergy is a distinctive feature of Ukraine’s model: the country’s established software development industry provides talent and methodological foundations that can be redirected toward biological applications.
The wartime context has paradoxically accelerated certain regulatory and industrial processes. Biopharma president Kostiantyn Yefymenko stated that “the war paradoxically became a factor that stimulates deregulation and acceleration of industrial projects,” noting that “today, building a plant is a matter of two years” . This deregulatory momentum, combined with the urgent demand for medical solutions for wounded soldiers, has created a permissive environment for rapid innovation deployment.
- Verified Scientific and Technical Advances
AI-Powered Phage Therapy for Antibiotic Resistance
The most concrete and strategically significant AI-biotech initiative is the phage therapy project launched in November 2025 through a Memorandum of Cooperation between Ukraine’s Ministry of Digital Transformation, Ministry of Health, Feofania Clinical Hospital, and British company GutSee Health Limited . The project uses artificial intelligence to select personalized bacteriophage treatments for antibiotic-resistant bacterial infections in severely wounded military personnel.
The technical approach, developed by GutSee Health under the PhageX platform, uses AI to match bacteriophages (viruses that attack bacteria) to specific infections within minutes, rather than the days or weeks required by traditional culture-based methods . GutSee Health’s CFO described the origin: the technology was initially developed for civilian applications (irritable bowel syndrome, inflammatory bowel disease) before its potential for treating infected wounds and dysentery in wartime conditions became apparent .
This project is explicitly described by Ukrainian officials as “the first project of this scale in Eastern Europe, combining medicine, biotechnology, and artificial intelligence” . The Feofania Clinical Hospital serves as the pilot clinical center for research, testing, and evaluation of the AI-selected phage treatments .
AI for IVF: Gamow Tech’s ReSpindle Platform
A separate, commercially oriented AI-biotech development is the Gamow Tech startup, which secured an undisclosed Seed round from Ukrainian venture fund ZAS Ventures in October 2025 at a valuation of €2.4 million . The company’s flagship product, ReSpindle, uses computer vision to analyze microscopic images of human oocytes (egg cells) and assess their viability before fertilization, detecting chromosomal abnormalities non-invasively .
The founding team combines Ukrainian biological expertise (embryologist Pavlo Mazur, biophysicist Kostiantyn Hnennyi) with deep-tech entrepreneurship and software engineering talent . Gamow Tech has signed research agreements with nine IVF clinics across different countries, covering more than 1% of the global IVF market . The investment will support clinical validation and preparation for CE certification in the EU .
Computational Biology at the National Academy of Sciences
Ukraine’s National Academy of Sciences has produced foundational work in AI-driven computational biology. Academician Mykhailo Zgurovsky highlighted the GRAMCELL platform, which for the first time enables modeling not only of protein structures but also of protein system interactions within cells, accelerating simulation “by at least two orders of magnitude” . This opens possibilities for machine-assisted drug synthesis and dramatically reduces development timelines.
The work integrates classical mathematics (Markov decision processes, partially observable systems, reinforcement learning) with AI, an approach Zgurovsky compared to the 2024 Nobel Prize-winning work in physics and chemistry . Pavlo Kasyanov, a key researcher in this school, was elected a foreign member of the US National Academy of Sciences in AI, an external validation of Ukrainian computational biology’s international standing .
The Academy’s July 2025 AI Development Strategy identified fundamental AI theory and its application in science and technology as Ukraine’s competitive niche, and recommended a targeted scientific program on modeling complex processes through AI integration .
Pharmaceutical and Biotechnology Infrastructure
Biopharma, Ukraine’s leading plasma-derived pharmaceutical company, is completing one of Europe’s largest blood plasma processing facilities in Uzhhorod, Zakarpattia. The €75 million first phase will process 1.5 million liters of plasma annually, enabling a full cycle of blood plasma processing within Ukraine for the first time . The company is simultaneously building a second plant in Arad, Romania, forming a production cluster with combined capacity far exceeding its existing Bila Tserkva facility (700,000 liters annually) .
Biopharma’s digitalization efforts include SAP ERP for operations, TrackWise for quality management (covering over 4,000 procedures), a proprietary donor management system, and fully digitized regulatory dossier submissions . The company states it is “actively investing in digitalization and artificial intelligence,” though specific AI applications in its production processes are not detailed in available sources .
Regional Innovation Infrastructure
In April 2026, a BioMedTech Science Park was established in Lviv through a memorandum between the Lviv Regional Development Agency, Danylo Halytskyi Lviv National Medical University, the Institute of Cell Biology of the National Academy of Sciences, and Doctor Eleks . The park aims to integrate basic science, medical education, clinical practice, and technology, with rehabilitation and prosthetics identified as particular priorities given wartime needs . The initiative explicitly seeks to connect Ukrainian networks into European innovation and research frameworks.
- Institutional and Human Capital Landscape
Ukraine’s AI-biotech ecosystem is characterized by a distributed, partnership-driven structure rather than centralized state direction. Key institutional actors include:
· Ministry of Digital Transformation: Coordinates the WINWIN Strategy and serves as the primary government counterpart for international AI-biotech partnerships .
· Ministry of Health: Provides regulatory support and healthcare system integration .
· National Academy of Sciences: Houses foundational AI research (Zgurovsky school, GRAMCELL platform) and the Institute of Cell Biology .
· Feofania Clinical Hospital: Serves as the pilot clinical center for AI-phage therapy, providing the clinical infrastructure for testing novel treatments .
· Private sector: Biopharma (plasma products, €500 million expansion plan over 10 years), GutSee Health (AI-phage therapy, UK-based but operating in Ukraine), Gamow Tech (AI-IVF diagnostics) .
The human capital dimension is notable. Biopharma has established two Bio-Schools (in Kyiv and Bila Tserkva) providing free intensive instruction in mathematics, chemistry, and biology (10 hours per week), with plans for 25–30 additional Bio-Schools across Ukraine . This represents a private-sector investment in the long-term talent pipeline for biotechnology.
- Analytical Assessment: Strengths, Weaknesses, and Strategic Trajectory
Strengths. Ukraine’s AI-biotech sector demonstrates genuine agility in translating research into clinical applications. The AI-phage therapy project moved from concept to signed memorandum and pilot implementation within a compressed timeframe, driven by wartime urgency and facilitated by Western partnership . The IT-biotech synergy identified in academic analysis is real: Gamow Tech exemplifies how Ukrainian software talent can be redirected to biological problems . The GRAMCELL platform’s international recognition (US NAS membership for Kasyanov) provides external validation of foundational capabilities .
Weaknesses. The sector lacks a domestic AI infrastructure comparable to Russia’s state-directed compute and model development programs. Ukraine’s AI-biotech advances rely heavily on foreign technology partners (GutSee Health’s AI expertise, European GMP equipment for Biopharma) . Institutional coordination, while improving, remains fragmented: the WINWIN Strategy and Bioeconomy Concept exist, but their implementation mechanisms are not yet fully integrated . Most critically, published peer-reviewed output from Ukrainian AI-biotech research remains limited relative to the volume of strategic documents and press releases.
Strategic Trajectory. Ukraine appears to be pursuing a niche specialization strategy focused on applications where wartime needs create both urgency and a permissive testing environment: trauma care, antibiotic resistance, rehabilitation, and reproductive medicine for a population under demographic stress. This differs fundamentally from Russia’s approach of building comprehensive sovereign AI-biotech infrastructure. Ukraine’s model is partnership-dependent and application-focused; Russia’s is sovereignty-oriented and infrastructure-heavy. The former offers faster deployment of specific solutions; the latter offers greater long-term autonomy but slower translation to practical applications.
The critical variable for Ukraine’s trajectory will be whether the wartime innovation momentum and international partnerships can be institutionalized into durable peacetime capabilities. The Bio-Schools, the BioMedTech Science Park in Lviv, and the GRAMCELL research program represent early efforts in this direction, but their long-term sustainability remains unproven .
